Classifying IDH Mutant Glioma

Isocitrate dehydrogenase is an enzyme that plays a role in normal cell metabolism. In healthy cells, it helps convert nutrients into energy in a controlled and efficient way. In many gliomas, however, a mutation develops in the IDH gene. This mutation changes how the enzyme works and leads to the production of an abnormal substance that interferes with normal cell development.

Paradoxically, while IDH mutations contribute to tumor formation, gliomas with this mutation tend to grow more slowly and behave in a less aggressive way than tumors without the mutation. This is why IDH status has become such an important dividing line in glioma classification. Tumors are now broadly grouped into those that are IDH-mutant and those that are IDH-wild type, meaning the gene remains normal.

The presence or absence of an IDH mutation does not just label the tumor; it fundamentally changes how the tumor is understood, how it is named, and how it is treated. This represents a major change from older classification systems that relied mostly on how tumor cells looked under the microscope.

How Are IDH Mutations Tested?

IDH mutations are detected through molecular testing of tumor tissue. This tissue is usually obtained during surgery or, in some cases, a biopsy. After the procedure, the tumor sample is sent to a specialized laboratory where pathologists and molecular scientists analyze it in detail.

Testing can be done using several methods, including immunohistochemistry (IHC), which looks for abnormal protein expression, or more advanced genetic sequencing techniques that directly analyze the tumor’s DNA. These tests are now considered standard for glioma diagnosis and are recommended for nearly all patients. Dr. Michal Nisnboym Ziv, a neuro-oncologist at the University of Pittsburgh Medical Center, explains that in general “immunohistochemistry stains are the first step…and if it’s positive we can know just by doing the IHC, which is within a few days,” but if the mutation is uncommon, then “…only by doing the genetic and molecular testing, which lead us to wait for around 10 to 14 days”. Your care team will review these findings with you and explain how they affect your diagnosis and treatment plan.

How Does Prognosis Differ Between IDH-Mutant and IDH-Wild-Type Gliomas?

One of the most important reasons IDH status matters is its strong relationship to prognosis. In general, patients with IDH-mutant gliomas tend to live longer and experience slower tumor growth compared with patients whose tumors are IDH-wild type. These tumors often respond better to treatment and may remain stable for many years.

IDH-wild-type gliomas, on the other hand, tend to behave more aggressively and may progress more quickly. Even when they appear low-grade under the microscope, IDH-wild-type tumors often act more like higher-grade tumors clinically. This distinction helps doctors determine how closely to monitor the tumor and how aggressively to treat it.

It is important to remember that prognosis is influenced by many factors, including age, overall health, extent of tumor removal, and other molecular features. IDH status provides important information, but it is only one part of the overall picture.

Other Molecular Markers Used in Glioma Classification

In addition to IDH, several other molecular markers help further define glioma subtypes. One of the most important is the presence or absence of a combined deletion of chromosome arms 1p and 19q. This marker is critical for diagnosing oligodendrogliomas and is associated with better response to chemotherapy and radiation.

Another important marker is ATRX, a gene involved in maintaining chromosome stability. Loss of ATRX function is commonly seen in astrocytomas and helps distinguish them from other tumor types. TP53, a well-known tumor suppressor gene, is also frequently altered in certain gliomas and provides additional diagnostic information.

In higher-grade tumors, markers such as MGMT promoter methylation, EGFR amplification, and TERT promoter mutations may be evaluated. These features can influence prognosis and guide treatment decisions, particularly in more aggressive gliomas.

Together, these molecular markers allow doctors to classify gliomas more precisely than ever before, leading to more tailored treatment strategies.

Understanding the Difference Between Oligodendroglioma and Astrocytoma

Two of the most common types of IDH-mutant gliomas are oligodendrogliomas and astrocytomas. While they may share some features, they are considered distinct tumor types with different molecular signatures and clinical behaviors.

Oligodendrogliomas are defined by the presence of both an IDH mutation and the 1p/19q codeletion. These tumors often grow slowly and tend to respond very well to treatment. Many patients with oligodendrogliomas live for many years, and long-term disease control is common.

Astrocytomas, in contrast, have an IDH mutation but do not have the 1p/19q codeletion. Instead, they often show changes in ATRX and TP53. Astrocytomas can also grow slowly, particularly at lower grades, but their behavior is more variable than that of oligodendrogliomas.

The distinction between these two tumor types is important because it affects prognosis, treatment recommendations, and long-term follow-up strategies.

What This Means for You as a Patient

The shift toward molecular-based glioma classification represents a major advance in patient care. By understanding the genetic makeup of a tumor, doctors can provide more accurate diagnoses, better estimates of prognosis, and more individualized treatment plans.

 

 

Learn more about SurvivorNet's rigorous medical review process.

---